Fineimmu announced that it has received nearly CNY 100,000,000 in its pre-series A round of funding led by Huafang Investment on August 3, 2022. The transaction included participation from Yabao Pharmaceutical Group Co., Ltd and Panacea Venture Management Co., Ltd.